Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | TP53 | P04637 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.70 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.70 |
| ▸ | NT5E | P21589 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10427399 | 1.00 | PNP (0.70) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL10427400 | 1.00 | PNP (0.70) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL28907819 | 0.89 | LMNA (0.54) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL23586006 | 0.87 | PDE4D (0.55) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL16366033 | 0.87 | PNP (0.77) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL12746240 | 0.87 | PNP (0.77) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL21545820 | 0.87 | NT5E (0.54) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL887526 | 0.87 | NT5E (0.54) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL10022904 | 0.87 | NT5E (0.54) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL16366051 | 0.85 | PNP (0.74) | PNPLMNATP53HTTPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158425-A1 | MODIFIED ADENINES | NUCLERA LTD (GB) | 2024-05-16 | — | — | US | disclosed |
| US-20240059729-A1 | MULTIFUNCTIONAL CYCLIC DINUCLEOTIDE AND USE THEREOF | TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED (CN) | 2024-02-22 | — | — | US | disclosed |
| CN-117015383-A | Multifunctional cyclic dinucleotide and application thereof | 泰励生物科技（上海）有限公司 | 2023-11-07 | — | — | CN | disclosed |
| EP-4242218-A1 | MULTIFUNCTIONAL CYCLIC DINUCLEOTIDE AND USE THEREOF | Tyligand Bioscience (Shanghai) Limited (CN) | 2023-09-13 | — | — | EP | disclosed |
| CN-115160392-A | Multifunctional cyclic dinucleotide and application thereof | 泰励生物科技（上海）有限公司 | 2022-10-11 | — | — | CN | disclosed |
| WO-2022175684-A1 | MODIFIED ADENINES | NUCLERA NUCLEICS LTD (GB) | 2022-08-25 | — | — | WO | disclosed |
| WO-2022083584-A1 | MULTIFUNCTIONAL CYCLIC DINUCLEOTIDE AND USE THEREOF | 泰励生物科技（上海）有限公司 | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059729-A1 | MULTIFUNCTIONAL CYCLIC DINUCLEOTIDE AND USE THEREOF | MAVS, IRF3, STING1 | PNP 144/4885LMNA 2386/4885TP53 121/4885 |
| US-20240158425-A1 | MODIFIED ADENINES | RNGTT, ADAR, MRM1 | PNP 16/4885LMNA 680/4885TP53 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.